Homer Pearce

American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA.

American Chemical Society engages as a scientific society which supports scientific inquiry in the field of chemistry. The company was founded in 1876 and is headquartered in Washington, DC.

BioNumerik Pharmaceuticals, Inc. discovers and develops new medicines for cancer treatment. The firm's products include Tavocept which has the potential to substantially increase patient survival in the most common type of lung cancer and possibly many other forms of cancer, and Karenitecin which is an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. The company was founded by Frederick H. Hausheer on December 15, 1992 and is headquartered in San Antonio, TX.

Apexian Pharmaceuticals, Inc. discovers, develops and commercializes novel pharmaceuticals products. It offers pharmaceutical products for the treatment of pancreatic cancer, blood cancer, brain tumors, ovarian cancer, age-related macular degeneration, and diabetic retinopathy. The company was founded by Mark R. Kelley in 2005 and is headquartered in Indianapolis, IN.

Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington.

Catena Pharmaceuticals, Inc. is focused on the development and commercialization of novel GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's proprietary chemistry is uniquely capable of affecting a specific class of GPCRs known to be relevant in a variety of disease states. Catena focuses its research and product development efforts around manipulation of the biology of the blood-borne signaling molecule lysophosphatidic acid (LPA). Its products will either block the signaling of LPA, or reduce production of LPA, or mimic LPA. The company was founded by Kevin Lynch and Tim MacDonald in the year 2008 and is headquartered in Durham, NC.

Kylin Therapeutics, Inc., a cutting-edge biotechnology company, employs a revolutionary RNA nanoparticle technology platform called 'pRNA' to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. This visionary platform has enormous potential to meet the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform have enabled Kylin to overcome the most significant challenges in the development of RNA-based therapies. The formation of Kylin Therapeutics Inc., is a result of a joint partnership between IN-vivo Ventures, LLC, and Golden Pine Ventures, LLC. Together, these two companies can leverage their alliance partners and strong Board of Directors to ensure Kylin's success. A lean, cross-functional management team is set to effect early stage success. This team provides the essential ingredients to develop and promote Kylin to the next level. It is the goal of this team to provide early stage validation and market traction to attract world-class operational management with relevant credentials, track records, and operational experience.